MedTrace Logo

Study of Flavocoxid (Limbrel) vs Naproxen in Subjects With Mod-Severe Osteoarthritis of the Knee

NCT00435292 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2015-10-21

No results posted yet for this study

Summary

Randomized, double-blind, placebo controlled parallel group, multi center study in subjects with moderate-severe osteoarthritis.

Conditions

Interventions

DRUG

Naproxen

nonsteroidal anti-inflammatory drug

DIETARY_SUPPLEMENT

flavocoxid 250 mg

flavonoid mixture

DIETARY_SUPPLEMENT

flavocoxid 500 mg

flavonoid mixture

Sponsors & Collaborators

  • Primus Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Robert M Levy, MD · Primus Pharmaceuticals,Inc

  • Alan Kivitz, MD · Private Practice

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00435292 on ClinicalTrials.gov